Increasing NMDA Glutamate Receptor Instead of Blocking It Produces Antidepressant-Like Effects


Results from animal models of depression and a human clinical trial show that enhancing, instead of blocking, the NMDA glutamate receptor can cause antidepressant-like effects.

Studies have shown that ketamine works to produce antidepressant effects in depressed patients who had not responded to past treatments. It does this by blocking one of the targets for the brain neurotransmitter glutamate, the N-methyl-D-aspartate (NMDA) glutamate receptor. However, a new study concludes that enhancing, as opposed to blocking, the NMDA glutamate receptor can also cause antidepressant-like effects. The study was published in the November 15, 2013 issue of Biological Psychiatry.

Researchers from China Medical University Hospital in Taiwan worked in collaboration with scientists from University of California in Los Angeles to study sarcosine in an animal model of depression and, in another clinical trial, 40 patients with depression. Hsien-Yuan Lane, MD, Ph.D., the author of the article, noted in a press release, “We found that enhancing NMDA function can improve depression-like behaviors in rodent models and in human depression.”

For the six-week clinical trial, 40 patients were randomly assigned to receive sarcosine or citalopram (Celexa), an antidepressant already on the market that was used as the control. Neither the patients nor their doctors knew which drug they were receiving during the study. When compared to citalopram, patients who received sarcosine reported significantly improved mood scores, experienced relief of their depression symptoms, and were more likely to continue in the study. Neither group experienced any major side effects; however, the citalopram group reported more relatively minor side effects. Sarcosine improved scores of the Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function tests more than the citalopram treatment, the study noted.

Test rats were used to investigate the effects of sarcosine on NMDA glutamate receptor. The researchers conducted forced swim tests, tail suspension tests, elevated plus maze tests, novelty-suppressed feeding tests, and chronic unpredictable stress tests. Sarcosine decreased immobility in both the forced swim test and the tail suspension test. It reduced the latency to feed in the novelty-suppression feeding test and reversed behavioral deficits caused by the chronic unpredictable stress test. These effects are characteristic of an antidepressant.

Related Videos
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Depression Screening: Challenges and Solutions at the Primary Care Level
© 2024 MJH Life Sciences

All rights reserved.